Invitrogen and Illumina Announce Strategic Alliance
Synthesis, Distribution and Marketing Strengths For Global Life Sciences Customers
Invitrogen Corporation (NASDAQ: IVGN) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to leverage their respective strengths in nucleic acid synthesis and distribution to deliver oligonucleotides of unequaled value to the Life Sciences market worldwide. The collaboration will expand Illumina's Oligator� DNA synthesis technology and combine that capability with Invitrogen's extensive sales, marketing and distribution channels. Oligonucleotides (oligos) are small, synthetic pieces of DNA that are an essential component of all genetic research, and global researchers will benefit from access to oligos with industry-leading quality and value available in both tube and plate formats, as well as reliable order turnaround times.
Under the terms of the agreement, Invitrogen will invest $3.4 million in Illumina's San Diego facility to enable implementation of fourth-generation Oligator technology, extend the technology into tube-based oligo products and provide for transfer of the technology into two additional Invitrogen facilities outside North America. Over the next several quarters, the companies expect to transition all responsibility for sales, marketing and technical support to Invitrogen as Illumina builds its capability to manufacture tube-based oligos. Customers will experience a seamless transition as current ordering processes and sales representatives will remain intact. Profit from the collaboration products will be split equally between the two companies.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
